PET/CT measures ENDO-HDR response, may let patients skip chemo

01/30/2013 | AuntMinnie.com (free registration)

PET/CT imaging can determine pathological response in postsurgery patients with stage II and III rectal cancer who underwent short high-dose-rate endorectal brachytherapy prior to surgery, according to results presented at a gastrointestinal cancers meeting. ENDO-HDR may allow patients to avoid chemotherapy before surgery, researchers said. They also hope the method will allow for nonoperative management of many patients.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR